Thromboembolism
Conditions
Keywords
Pediatric
Brief summary
The purpose of this study is to find out whether rivaroxaban is safe and effective to use in children age newborn to less than 6 months and how long it stays in the body and how it is used in the body. Safety will be assessed by looking at the incidence and types of bleeding events. There will also be a check for worsening of blood clots.
Detailed description
Neonates and infants aged less than 6 months who pass the screen of in- and exclusion criteria, who have been treated for at least five days with heparin and /or vitamin K antagonist (VKA) for confirmed symptomatic or asymptomatic arterial or venous thrombosis are eligible for the study. Study treatment consists of a 7-day treatment with an age- and body weight-adjusted three times daily, approximately 8 hours apart oral rivaroxaban dosing to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban once daily. Rivaroxaban will be provided as granules for preparation of an oral suspension (1 mg/mL after re-suspension) using a t.i.d. regimen with 8-hour intervals. An ultrasound will be performed before starting rivaroxaban at treatment day 1 and after the end of rivaroxaban treatment at day 8. The last dose of rivaroxaban treatment will be followed by a 30-day post study treatment period, regardless of the duration of study drug administration. After cessation of rivaroxaban, it is at the investigator's discretion to continue with anticoagulants. The principal safety outcome is the combination of major and clinically relevant non-major bleeding. The efficacy outcome is the composite of all symptomatic recurrent thromboembolism and asymptomatic deterioration in thrombotic burden on repeat imaging. All suspected recurrent thromboembolism, asymptomatic deterioration in thrombotic burden on repeat imaging, deaths, as well as all episodes of bleeding will be evaluated by a central independent adjudication committee (CIAC). Adjudication results will be the basis for the final analyses. For all children, visits are scheduled at regular time points (see Table 1). Enrolled children who are not treated or those with premature discontinuation of rivaroxaban will at least be seen at the end of the study treatment period. During all contacts, the treatment and clinical course of the child will be evaluated. Children with suspected efficacy or safety outcomes will undergo confirmatory testing as per standard of care. Blood samples for pharmacokinetic (PK)/pharmacodynamics (PD) will be taken at defined time points (see Table 2). An Independent Data Monitoring Committee (DMC) will monitor the children's safety during the study and give recommendations to the steering committee.
Interventions
DRUGRivaroxaban (Xarelto, BAY59-7939)
Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venous thromboembolism (VTE) with 20 mg once daily.
Sponsors
Janssen Research & Development, LLC
Bayer
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 6 Months
Healthy volunteers
No
Inclusion criteria
* Children from birth to less than 6 months with documented symptomatic or asymptomatic venous or arterial thrombosis who have been treated with anticoagulant therapy for at least 5 days. * Gestational age at birth of at least 37 weeks. * Hemoglobin, platelets, creatinine, ALT and total and direct bilirubin assessed within 10 days prior to enrollment. * Oral feeding/nasogastric/gastric feeding for at least 10 days. * Informed consent provided. * Body weight \>2600 g
Exclusion criteria
* Active bleeding or high risk for bleeding contraindicating anticoagulant therapy, including history of intra-ventricular bleeding. * Symptomatic progression of thrombosis during preceding anticoagulant treatment. * Planned invasive procedures, including lumbar puncture and removal of non-peripherally placed central lines during study treatment. * Hepatic disease which is associated with either: coagulopathy leading to a clinically relevant bleeding risk, or alanine aminotransferase (ALT) \> 5x upper level of normal (ULN) or total bilirubin (TB) \> 2x ULN with direct bilirubin \> 20% of the total. * Creatinine \>1.5 times of normal. * Uncontrolled Hypertension defined as \>95th percentile. * History of gastrointestinal disease or surgery associated with impaired absorption. * Platelet count \<100 x 109/L. * Concomitant use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 (CYP3A4) and P-glycoprotein (P-gp), e.g. all human immunodeficiency virus protease inhibitors and the following azole-antimycotics agents: ketoconazole, itraconazole, voriconazole, posaconazole, if used systemically (fluconazole is allowed) * Concomitant use of strong inducers of CYP3A4, e.g. rifampicin, rifabutin, phenobarbital, phenytoin and carbamazepine * Indication for anticoagulant therapy other than current thrombosis. * Indication for antiplatelet therapy or non-steroid anti-inflammatory drug (NSAID) therapy. Incidental use is allowed. * Hypersensitivity to rivaroxaban or its excipients. * Participation in a study with an investigational drug or medical device within 30 days prior to enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anti-factor Xa Activity (Anti-Xa) Values at Day 8 | 10-16 hours post-dose on Day 8 (both bid and tid dosing) | The individual anti-Factor Xa activity was determined ex-vivo using a photometric method. |
| Anti-factor Xa Activity (Anti-Xa) Values at Day 1 | 2-4 hours after the first dose on Day 1 (bid dosing) and 7-8 hours after the first dose on Day 1 (tid dosing) | The individual anti-Factor Xa activity was determined ex-vivo using a photometric method. |
| Anti-factor Xa Activity (Anti-Xa) Values at Day 3 | 2-8 hours post-dose on Day 3 (bid dosing) and 0.5-3 hours post-dose on Day 3 (tid dosing) | The individual anti-Factor Xa activity was determined ex-vivo using a photometric method. |
| Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 1 | 30 minutes to 1.5 hours post-dose; 2 to 4 hours post-dose (bid dosing) and 30 minutes to 3 hours post-dose; 7 to 8 hours post-dose on Day 1 (tid dosing) | Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated. |
| Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 3 | 2 to 8 hours post-dose (bid dosing) and 30 minutes to 3 hours post-dose; 7 to 8 hours post-dose on Day 3 (tid dosing) | Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated. |
| Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 8 | 10 to 16 hours post-dose on Day 8 (bid dosing) | Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated. |
| Change From Baseline in Prothrombin Time at Day 1 | 10-16 hours post-dose on Day 8 (baseline), 2-4 hours after the first dose on Day 1 (bid dosing) and 7-8 hours after the first dose on Day 1 (tid dosing) | Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade. |
| Change From Baseline in Prothrombin Time at Day 3 | 10-16 hours post-dose on Day 8 (baseline), 2-8 hours post-dose on Day 3 (bid dosing) and 0.5-3 hours post-dose on Day 3 (tid dosing) | Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade. |
| Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 1 | 10-16 hours post-dose on Day 8 (baseline), 2-4 hours after the first dose on Day 1 (bid dosing) and 7-8 hours after the first dose on Day 1 (tid dosing) | The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway and is sensitive for deficiencies of factors I, II, V, VIII, IX, X, XI and XII. |
| Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 3 | 10-16 hours post-dose on Day 8 (baseline), 2-8 hours post-dose on Day 3 (bid dosing) and 0.5-3 hours post-dose on Day 3 (tid dosing) | The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway and is sensitive for deficiencies of factors I, II, V, VIII, IX, X, XI and XII. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Symptomatic Recurrent Venous Thromboembolism and Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging | From start of study drug administration until 30-day post study treatment period | Symptomatic recurrence of thromboembolism and asymptomatic deterioration was documented using the appropriate imaging test and confirmed by CIAC which was unaware of treatment assignment. Asymptomatic deterioration in thrombotic burden on repeat imaging, as assessed by the CIAC. Adjudication results were the basis for the final analyses. |
| Number of Participants With Major and Clinically Relevant Non-Major Bleeding Events | From start of study drug administration until 30-day post study treatment period | Central independent adjudication committee (CIAC) classified bleeding as follows: Major bleeding is defined as overt bleeding and •associated with a fall in hemoglobin of 2 gram/deciliter (g/dL) or more, •leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or •occurring in a critical site, example: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or •contributing to death. Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for major bleeding, but associated with: •medical intervention, or •unscheduled contact (visit or telephone call) with a physician, or •cessation (temporary) of study treatment, or •discomfort for the child such as pain |
Countries
Austria, France, Germany, Israel, Italy, Spain, Turkey (Türkiye)
Participant flow
Recruitment details
Study was conducted at 9 study centers in 7 countries between 19 November 2015 (first participant first visit) and 18 December 2017 (last participant last visit).
Pre-assignment details
Overall, 11 participants were screened, of these 1 participant was not included in the study due to withdrawal by parent. A total of 10 participants were assigned to treatment.
Participants by arm
| Arm | Count |
|---|---|
| Rivaroxaban (BAY59-7939) Suspension Bid Participants aged less than 6 months were administered with age- and body weight-adjusted 0.5 to 3.2 milligram (mg) oral dose of rivaroxaban oral suspension twice daily (bid) for 7 days. | 5 |
| Rivaroxaban (BAY59-7939) Suspension Tid Participants aged less than 6 months were administered with age- and body weight-adjusted 0.5 to 2.9 mg oral dose of rivaroxaban oral suspension thrice daily (tid) for 7 days. | 5 |
| Total | 10 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Withdrew from treatment | 0 | 1 |
Baseline characteristics
| Characteristic | Total | Rivaroxaban (BAY59-7939) Suspension Tid | Rivaroxaban (BAY59-7939) Suspension Bid |
|---|---|---|---|
| Activated Partial Thromboplastin Time (aPTT) | NA Seconds (sec) | 34.9 Seconds (sec) STANDARD_DEVIATION 2.62 | 34.0 Seconds (sec) STANDARD_DEVIATION 4.05 |
| Age, Continuous | 1.47 Months STANDARD_DEVIATION 1.59 | 1.12 Months STANDARD_DEVIATION 0.6 | 1.81 Months STANDARD_DEVIATION 2.24 |
| Prothrombin Time | NA Seconds (sec) | 13.9 Seconds (sec) STANDARD_DEVIATION 1.31 | 13.3 Seconds (sec) STANDARD_DEVIATION 0.378 |
| Race/Ethnicity, Customized Black or African American | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Unknown or Not Reported | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized White | 8 Participants | 5 Participants | 3 Participants |
| Sex: Female, Male Female | 5 Participants | 4 Participants | 1 Participants |
| Sex: Female, Male Male | 5 Participants | 1 Participants | 4 Participants |
| Weight | 4.02 Kilogram (kg) STANDARD_DEVIATION 1.6 | 3.70 Kilogram (kg) STANDARD_DEVIATION 0.85 | 4.33 Kilogram (kg) STANDARD_DEVIATION 2.19 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 5 | 0 / 5 |
| other Total, other adverse events | 1 / 5 | 0 / 5 |
| serious Total, serious adverse events | 0 / 5 | 1 / 5 |
Outcome results
Primary
Anti-factor Xa Activity (Anti-Xa) Values at Day 1
The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.
Time frame: 2-4 hours after the first dose on Day 1 (bid dosing) and 7-8 hours after the first dose on Day 1 (tid dosing)
Population: PDS included all participants with at least 1 blood sample for clotting parameters in accordance with the PD sampling strategy were included in the PD analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Rivaroxaban (BAY59-7939) Suspension Bid | Anti-factor Xa Activity (Anti-Xa) Values at Day 1 | 63.3 microgram per liter (mcg/L) | Standard Deviation 60.8 |
| Rivaroxaban (BAY59-7939) Suspension Tid | Anti-factor Xa Activity (Anti-Xa) Values at Day 1 | 18.0 microgram per liter (mcg/L) | Standard Deviation 8.37 |
Primary
Anti-factor Xa Activity (Anti-Xa) Values at Day 3
The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.
Time frame: 2-8 hours post-dose on Day 3 (bid dosing) and 0.5-3 hours post-dose on Day 3 (tid dosing)
Population: PDS included all participants with at least 1 blood sample for clotting parameters in accordance with the PD sampling strategy were included in the PD analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Rivaroxaban (BAY59-7939) Suspension Bid | Anti-factor Xa Activity (Anti-Xa) Values at Day 3 | 67.3 microgram per liter (mcg/L) | Standard Deviation 48.7 |
| Rivaroxaban (BAY59-7939) Suspension Tid | Anti-factor Xa Activity (Anti-Xa) Values at Day 3 | 59.8 microgram per liter (mcg/L) | Standard Deviation 46.8 |
Primary
Anti-factor Xa Activity (Anti-Xa) Values at Day 8
The individual anti-Factor Xa activity was determined ex-vivo using a photometric method.
Time frame: 10-16 hours post-dose on Day 8 (both bid and tid dosing)
Population: PDS included all participants with at least 1 blood sample for clotting parameters in accordance with the PD sampling strategy were included in the PD analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Rivaroxaban (BAY59-7939) Suspension Bid | Anti-factor Xa Activity (Anti-Xa) Values at Day 8 | 7.25 microgram per liter (mcg/L) | Standard Deviation 0 |
| Rivaroxaban (BAY59-7939) Suspension Tid | Anti-factor Xa Activity (Anti-Xa) Values at Day 8 | 9.92 microgram per liter (mcg/L) | Standard Deviation 5.35 |
Primary
Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 1
The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway and is sensitive for deficiencies of factors I, II, V, VIII, IX, X, XI and XII.
Time frame: 10-16 hours post-dose on Day 8 (baseline), 2-4 hours after the first dose on Day 1 (bid dosing) and 7-8 hours after the first dose on Day 1 (tid dosing)
Population: PDS included all participants with at least 1 blood sample for clotting parameters in accordance with the PD sampling strategy were included in the PD analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Rivaroxaban (BAY59-7939) Suspension Bid | Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 1 | 13.6 seconds (sec) | Standard Deviation 12.4 |
| Rivaroxaban (BAY59-7939) Suspension Tid | Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 1 | 2.33 seconds (sec) | Standard Deviation 5.53 |
Primary
Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 3
The Activated partial thromboplastin time (aPTT) is a screening test for the intrinsic pathway and is sensitive for deficiencies of factors I, II, V, VIII, IX, X, XI and XII.
Time frame: 10-16 hours post-dose on Day 8 (baseline), 2-8 hours post-dose on Day 3 (bid dosing) and 0.5-3 hours post-dose on Day 3 (tid dosing)
Population: PDS included all participants with at least 1 blood sample for clotting parameters in accordance with the PD sampling strategy were included in the PD analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Rivaroxaban (BAY59-7939) Suspension Bid | Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 3 | 7.02 seconds (sec) | Standard Deviation 5.08 |
| Rivaroxaban (BAY59-7939) Suspension Tid | Change From Baseline in Activated Partial Thromboplastin Time (aPTT) at Day 3 | 3.47 seconds (sec) | Standard Deviation 7.59 |
Primary
Change From Baseline in Prothrombin Time at Day 1
Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade.
Time frame: 10-16 hours post-dose on Day 8 (baseline), 2-4 hours after the first dose on Day 1 (bid dosing) and 7-8 hours after the first dose on Day 1 (tid dosing)
Population: Pharmacodynamic (PD) analysis set (PDS) included all participants with at least 1 blood sample for clotting parameters in accordance with the PD sampling strategy were included in the PD analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Rivaroxaban (BAY59-7939) Suspension Bid | Change From Baseline in Prothrombin Time at Day 1 | 11.6 seconds (sec) | Standard Deviation 17.3 |
| Rivaroxaban (BAY59-7939) Suspension Tid | Change From Baseline in Prothrombin Time at Day 1 | 0.025 seconds (sec) | Standard Deviation 0.714 |
Primary
Change From Baseline in Prothrombin Time at Day 3
Prothrombin time is a global clotting test used for the assessment of the extrinsic pathway of the blood coagulation cascade.
Time frame: 10-16 hours post-dose on Day 8 (baseline), 2-8 hours post-dose on Day 3 (bid dosing) and 0.5-3 hours post-dose on Day 3 (tid dosing)
Population: PDS included all participants with at least 1 blood sample for clotting parameters in accordance with the PD sampling strategy were included in the PD analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Rivaroxaban (BAY59-7939) Suspension Bid | Change From Baseline in Prothrombin Time at Day 3 | 3.74 seconds (sec) | Standard Deviation 2.84 |
| Rivaroxaban (BAY59-7939) Suspension Tid | Change From Baseline in Prothrombin Time at Day 3 | 1.13 seconds (sec) | Standard Deviation 2.1 |
Primary
Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 1
Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated.
Time frame: 30 minutes to 1.5 hours post-dose; 2 to 4 hours post-dose (bid dosing) and 30 minutes to 3 hours post-dose; 7 to 8 hours post-dose on Day 1 (tid dosing)
Population: Pharmacokinetic (PK) analysis set (PKS) included all participants with at least one PK sample in accordance with the PK sampling strategy.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Rivaroxaban (BAY59-7939) Suspension Bid | Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 1 | 30 minutes to 1.5 hours post-dose | 85.2001 microgram per liter (mcg/L) | Geometric Coefficient of Variation 37.72 |
| Rivaroxaban (BAY59-7939) Suspension Bid | Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 1 | 2 to 4 hours post-dose | 73.7641 microgram per liter (mcg/L) | Geometric Coefficient of Variation 64.38 |
| Rivaroxaban (BAY59-7939) Suspension Tid | Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 1 | 30 minutes to 3 hours post-dose | 42.6837 microgram per liter (mcg/L) | Geometric Coefficient of Variation 39.35 |
| Rivaroxaban (BAY59-7939) Suspension Tid | Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 1 | 7 to 8 hours post-dose | 12.1027 microgram per liter (mcg/L) | Geometric Coefficient of Variation 130.13 |
Primary
Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 3
Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated.
Time frame: 2 to 8 hours post-dose (bid dosing) and 30 minutes to 3 hours post-dose; 7 to 8 hours post-dose on Day 3 (tid dosing)
Population: PKS included all participants with at least one PK sample in accordance with the PK sampling strategy.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Rivaroxaban (BAY59-7939) Suspension Bid | Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 3 | 2 to 8 hours post-dose | 102.3285 microgram per liter (mcg/L) | Geometric Coefficient of Variation 40.36 |
| Rivaroxaban (BAY59-7939) Suspension Tid | Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 3 | 30 minutes to 3 hours post-dose | 32.2879 microgram per liter (mcg/L) | Geometric Coefficient of Variation 267.05 |
| Rivaroxaban (BAY59-7939) Suspension Tid | Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 3 | 7 to 8 hours post-dose | 9.1716 microgram per liter (mcg/L) | Geometric Coefficient of Variation 160.52 |
Primary
Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 8
Concentration of pharmacokinetic parameters of rivaroxaban in plasma was evaluated.
Time frame: 10 to 16 hours post-dose on Day 8 (bid dosing)
Population: PKS included all participants with at least one PK sample in accordance with the PK sampling strategy.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Rivaroxaban (BAY59-7939) Suspension Bid | Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 8 | 2.5696 microgram per liter (mcg/L) | Geometric Coefficient of Variation 70.82 |
| Rivaroxaban (BAY59-7939) Suspension Tid | Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 8 | NA microgram per liter (mcg/L) | — |
Secondary
Number of Participants With Major and Clinically Relevant Non-Major Bleeding Events
Central independent adjudication committee (CIAC) classified bleeding as follows: Major bleeding is defined as overt bleeding and •associated with a fall in hemoglobin of 2 gram/deciliter (g/dL) or more, •leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or •occurring in a critical site, example: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or •contributing to death. Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for major bleeding, but associated with: •medical intervention, or •unscheduled contact (visit or telephone call) with a physician, or •cessation (temporary) of study treatment, or •discomfort for the child such as pain
Time frame: From start of study drug administration until 30-day post study treatment period
Population: Safety analysis set (SAF) included all participants who received at least one dose of rivaroxaban.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Rivaroxaban (BAY59-7939) Suspension Bid | Number of Participants With Major and Clinically Relevant Non-Major Bleeding Events | Major bleeding events | 0 count of participants |
| Rivaroxaban (BAY59-7939) Suspension Bid | Number of Participants With Major and Clinically Relevant Non-Major Bleeding Events | Clinically relevant non-major bleeding events | 0 count of participants |
| Rivaroxaban (BAY59-7939) Suspension Tid | Number of Participants With Major and Clinically Relevant Non-Major Bleeding Events | Major bleeding events | 0 count of participants |
| Rivaroxaban (BAY59-7939) Suspension Tid | Number of Participants With Major and Clinically Relevant Non-Major Bleeding Events | Clinically relevant non-major bleeding events | 0 count of participants |
Secondary
Number of Participants With Symptomatic Recurrent Venous Thromboembolism and Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging
Symptomatic recurrence of thromboembolism and asymptomatic deterioration was documented using the appropriate imaging test and confirmed by CIAC which was unaware of treatment assignment. Asymptomatic deterioration in thrombotic burden on repeat imaging, as assessed by the CIAC. Adjudication results were the basis for the final analyses.
Time frame: From start of study drug administration until 30-day post study treatment period
Population: Full analysis set (FAS) included all participants from whom informed consent was obtained and who contributed any data thereafter.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Rivaroxaban (BAY59-7939) Suspension Bid | Number of Participants With Symptomatic Recurrent Venous Thromboembolism and Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging | Symptomatic recurrent venous thromboembolism | 0 count of participants |
| Rivaroxaban (BAY59-7939) Suspension Bid | Number of Participants With Symptomatic Recurrent Venous Thromboembolism and Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging | Asymptomatic deterioration in thrombotic burden | 0 count of participants |
| Rivaroxaban (BAY59-7939) Suspension Tid | Number of Participants With Symptomatic Recurrent Venous Thromboembolism and Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging | Symptomatic recurrent venous thromboembolism | 0 count of participants |
| Rivaroxaban (BAY59-7939) Suspension Tid | Number of Participants With Symptomatic Recurrent Venous Thromboembolism and Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging | Asymptomatic deterioration in thrombotic burden | 0 count of participants |